ITM Power: 3 directors

A director at ITM Power bought 82,744 shares at 42p and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

ITM Power: FY24 improvements, cautious FY25 outlook

ITM Power has reported FY 2024 numbers with revenue more than tripling YoY to GBP16.5m (-9% vs cons. at GBP18.2m, +2% vs BGe at GBP16.2m) and a better than expected EBITDA loss at GBP30.5m (+30% vs cons. at -GBP44.0m and BGe at -GBP43.7m). Measures taken by Dennis Schulz (CEO) since late 2022, aime

Daily Healthcare - November 1st, 2024

ATOSS Software initiation: the writing is on the wall

We initiate coverage of ATOSS Software, a German workforce management vendor (not to be confused with unrelated Atos), which despite its high fundamental quality, is facing significant risks of slowing growth, difficulties to expand beyond DACH, technological disruption, insufficient reinvestment o

ONWARD Medical: ARC-EX recognised as one of TIME's Best Inventions of 2024

ONWARD Medical's investigational ARC-EX System was named one of TIME's Best Inventions of 2024, spotlighting its potential to improve life for SCI. Recognised for originality, efficacy, ambition, and impact, the ARC-EX System enables SCI patients to regain hand and arm function, as evidenced by the